Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy

Abroad (travel likely)RecruitingPHASE4

Conditions

Hypertrophic Cardiomyopathy (HCM)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

St. Luke's Hospital - Mid America Heart Institute, Kansas City, Missouri, United States
Contact: Study coordinator (Michael Nassif, MD) · mnassif@saint-lukes.org · 816-932-3458
Contact: Principal Investigator (Michael Nassif, MD)
Oregon Health & Science University, Portland, Oregon, United States
Contact: Study coordinator (Ahmad Masri, MD) · masria@ohsu.edu · 503-494-7551

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM)

Cardiomyopathy

Abroad (travel likely)Recruiting

Minato-ku, Japan

Pediatric Cardiomyopathy Mutation Analysis

Cardiomyopathies · Dilated Cardiomyopathy · Hypertrophic Cardiomyopathy

Abroad (travel likely)Recruiting

Indianapolis, United States

A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China

Hypertrophic Cardiomyopathy

Abroad (travel likely)Recruiting

Beijing, China · Beijing, China

Multicentre Hypertrophic Cardiomyopathy Registry

Hypertrophic Cardiomyopathy (HCM)

Abroad (travel likely)Recruiting

Manchester, United Kingdom